BECKY LEE KINKEAD portrait
  • Research Professor, Psychiatry

Research Keywords

  • Depression
  • Cancer Related Fatigue
  • Anxiety
  • Integrative Medicine

Languages

  • English, Fluent.

Publications

  • Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS (date unknown). Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Vol. 82, 866-874. Accepted, .
  • Cáceda R, Kinkead B, Owens MJ, Nemeroff CB (date unknown). Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. Vol. 25, 11748-56. Accepted, .
  • Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D (date unknown). Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Vol. 60, 1278-81. Accepted, .
  • Stowe ZN, Landry JC, Tang Z, Owens MJ, Kinkead B, Nemeroff CB (date unknown). The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: an in vivo study. Vol. 58, 165-72. Accepted, .
  • Binder EB, Kinkead B, Owens MJ, Nemeroff CB (date unknown). Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. Vol. 29, 2200-7. Accepted, .
  • Binder EB, Kinkead B, Owens MJ, Nemeroff CB (date unknown). The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Vol. 50, 856-72. Accepted, .
  • Binder EB, Kinkead B, Owens MJ, Nemeroff CB (date unknown). Neurotensin and dopamine interactions. Vol. 53, 453-86. Accepted, .
  • Kinkead B, Owens MJ, Nemeroff CB (date unknown). The effects of acute antipsychotic drug administration on the neurotensin system of the developing rat brain. Vol. 124, 1-10. Accepted, .
  • Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush AJ, Thase ME, Yonkers KA, Rapaport MH (date unknown). The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis. Vol. 74, 1084-91. Accepted, .
  • Larson ER, Kinkead B, Edwards SA, Schettler PJ, Dunlop BW, Rakofsky JJ, Rapaport MH (date unknown). Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. Vol. 16. Accepted, .
  • Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, O'Dushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL, Consortium on the Genetics of Schizophrenia (COGS) Investigators., Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA, Genomic Psychiatry Cohort (GPC) Consortium., Fanous AH, Pato MT, McCarroll SA, Pato CN (date unknown). Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Vol. 25, 2455-2467. Accepted, .
  • Cáceda R, Kinkead B, Nemeroff CB (date unknown). Neurotensin: role in psychiatric and neurological diseases. Vol. 27, 2385-404. Accepted, .
  • Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB (date unknown). Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. Vol. 315, 256-64. Accepted, .
  • Kinkead B, Shahid S, Owens MJ, Nemeroff CB (date unknown). Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. Vol. 295, 67-73. Accepted, .
  • Kinkead B, Lorch SM, Owens MJ, Nemeroff CB (date unknown). Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain. Vol. 295, 205-11. Accepted, .
  • Garlow SJ, Kinkead B, Thase ME, Judd LL, Rush AJ, Yonkers KA, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH (date unknown). Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. Vol. 47, 1199-203. Accepted, .
  • Thrivikraman KV, Kinkead B, Murray KE, Owens MJ (date unknown). In vivo dialysis setup with a loop injection valve facilitates retrodialysis studies. Vol. 68, 217-224. Accepted, .
  • Kinkead B, Nemeroff CB (date unknown). The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Vol. 55 Suppl B, 30-2. Accepted, .
  • Coccaro EF, Lee R, Owens MJ, Kinkead B, Nemeroff CB (date unknown). Cerebrospinal fluid substance P-like immunoreactivity correlates with aggression in personality disordered subjects. Vol. 72, 238-43. Accepted, .
  • Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, Neumeister A, Yuan P, Kinkead B, Manji HK, Charney DS, Vythilingam M (date unknown). Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. Vol. 72, 1124-8. Accepted, .
  • Kinkead B, Binder EB, Nemeroff CB (date unknown). Does neurotensin mediate the effects of antipsychotic drugs?. Vol. 46, 340-51. Accepted, .
  • Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS (date unknown). Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Vol. 13, 106. Accepted, .
  • Rapaport MH, Schettler P, Larson ER, Edwards SA, Dunlop BW, Rakofsky JJ, Kinkead B (date unknown). Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study. Vol. 77, e883-91. Accepted, .
  • Mandell AJ, Selz KA, Owens MJ, Kinkead B, Shlesinger MF, Gutman DA, Arguragi V (date unknown). Cellular and behavioral effects of D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands. Vol. 28 Suppl 1, S98-107. Accepted, .
  • Kinkead B, Owens MJ, Nemeroff CB (date unknown). Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain. Vol. 20, 244-8. Accepted, .
  • Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS (date unknown). Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Vol. 15, 240. Accepted, .
  • Waserstein G, Partin C, Cohen D, Schettler P, Kinkead B, Rapaport MH (date unknown). The prevalence and impact of psychiatric symptoms in an undiagnosed diseases clinical program. Vol. 14, e0216937. Accepted, .
  • Dunlop BW, Rajendra JK, Craighead WE, Kelley ME, McGrath CL, Choi KS, Kinkead B, Nemeroff CB, Mayberg HS (date unknown). Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. Vol. 174, 533-545. Accepted, .
  • Dunlop BW, Kelley ME, Aponte-Rivera V, Mletzko-Crowe T, Kinkead B, Ritchie JC, Nemeroff CB, Craighead WE, Mayberg HS, PReDICT Team. (date unknown). Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. Vol. 174, 546-556. Accepted, .
  • Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI (date unknown). Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Vol. 5, 21. Accepted, .
  • Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE (date unknown). Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. Vol. 176, 275-286. Accepted, .
  • Cáceda R, Binder EB, Kinkead B, Nemeroff CB (date unknown). The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion. Vol. 136, 88-95. Accepted, .
  • Wilson ME, Kinkead B (date unknown). Gene-environment interactions, not neonatal growth hormone deficiency, time puberty in female rhesus monkeys. Vol. 78, 736-43. Accepted, .
  • Hoffman JB, Kaplan JR, Kinkead B, Berga SL, Wilson ME (date unknown). Metabolic and reproductive consequences of the serotonin transporter promoter polymorphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta). Vol. 31, 202-11. Accepted, .
  • Kinkead B, Nemeroff CB (date unknown). Novel treatments of schizophrenia: targeting the neurotensin system. Vol. 5, 205-18. Accepted, .
  • Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB (date unknown). Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Vol. 163, 637-43. Accepted, .
  • Cáceda R, Kinkead B, Nemeroff CB (date unknown). Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?. Vol. 8, 94-108. Accepted, .
  • Jarrell H, Hoffman JB, Kaplan JR, Berga S, Kinkead B, Wilson ME (date unknown). Polymorphisms in the serotonin reuptake transporter gene modify the consequences of social status on metabolic health in female rhesus monkeys. Vol. 93, 807-19. Accepted, .
  • Chastain LG, Qu H, Bourke CH, Iuvone PM, Dobner PR, Nemeroff CB, Kinkead B (date unknown). Striatal dopamine receptor plasticity in neurotensin deficient mice. Vol. 280, 160-71. Accepted, .
  • Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT, Genomic Psychiatry Cohort Consortium. (date unknown). Comorbidity of severe psychotic disorders with measures of substance use. Vol. 71, 248-54. Accepted, .
  • Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS (date unknown). A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Vol. 21, 221-9. Accepted, .
  • Garlow SJ, Boone E, Kinkead B, Nemeroff CB (date unknown). Genetic analysis of the hypothalamic neurotensin system. Vol. 31, 535-43. Accepted, .
  • Welberg LA, Kinkead B, Thrivikraman K, Huerkamp MJ, Nemeroff CB, Plotsky PM (date unknown). Ketamine-xylazine-acepromazine anesthesia and postoperative recovery in rats. Vol. 45, 13-20. Accepted, .
  • Kinkead B, Selz KA, Owens MJ, Mandell AJ (date unknown). Algorithmically designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism. Vol. 151, 68-81. Accepted, .
  • Czamara D, Tissink E, Tuhkanen J, Martins J, Awaloff Y, Drake AJ, Khulan B, Palotie A, Winter SM, Nemeroff CB, Craighead WE, Dunlop BW, Mayberg HS, Kinkead B, Mathew SJ, Iosifescu DV, Neylan TC, Heim CM, Lahti J, Eriksson JG, Räikkönen K, Ressler KJ, Provençal N, Binder EB (date unknown). Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. Vol. 11, 88. Accepted, .
  • Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH, Torres MA, Dunlop BW, Rakofsky JJ, Rapaport MH (date unknown). Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Vol. 124, 546-554. Accepted, .
  • Kinkead B, Yan F, Owens MJ, Nemeroff CB (date unknown). Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats. Vol. 33, 178-87. Accepted, .
  • Kinkead B, Nemeroff CB (date unknown). Neurotensin: an endogenous antipsychotic?. Vol. 2, 99-103. Accepted, .
  • Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, Kinkead B, Owens MJ, Nemeroff CB (date unknown). Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Vol. 157, 123-9. Accepted, .
  • Binder EB, Kinkead B, Owens MJ, Kilts CD, Nemeroff CB (date unknown). Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. Vol. 21, 601-8. Accepted, .
  • Rapaport MH, Schettler PJ, Larson ER, Dunlop BW, Rakofsky JJ, Kinkead B (date unknown). Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings. Vol. 56, 102593. Accepted, .
  • Lamon-Fava S, So J, Mischoulon D, Ziegler TR, Dunlop BW, Kinkead B, Schettler PJ, Nierenberg AA, Felger JC, Maddipati KR, Fava M, Rapaport MH (date unknown). Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Vol. 164, 102219. Accepted, .
  • Loring DW, Meador KJ, Shinnar S, Gaillard WD, Wheless JW, Kessler SK, Conry JA, Berl MM, Burns TG, Glauser TA, Kinkead B, Cnaan A (date unknown). Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy. Vol. 102, 106687. Accepted, .
  • Rapaport MH, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Kinkead B (date unknown). Massage Therapy for Psychiatric Disorders. Vol. 16, 24-31. Accepted, .
  • Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (date unknown). Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Vol. 21, 71-9. Accepted, .
  • Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M (date unknown). A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. Vol. 76, 54-61. Accepted, .
  • Cáceda R, Kinkead B, Nemeroff CB (date unknown). Involvement of neuropeptide systems in schizophrenia: human studies. Vol. 78, 327-76. Accepted, .
  • Kinkead B, Nemeroff CB (date unknown). Neurotensin, schizophrenia, and antipsychotic drug action. Vol. 59, 327-49. Accepted, .
  • Nemeroff CB, Kinkead B, Goldstein J (date unknown). Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. Vol. 63 Suppl 13, 5-11. Accepted, .
  • Ehlers CL, Somes C, Li TK, Lumeng L, Kinkead B, Owens MJ, Nemeroff CB (date unknown). Neurontensin studies in alcohol naive, preferring and non-preferring rats. Vol. 93, 227-36. Accepted, .
  • Bissette G, Myers B (date unknown). Somatostatin in Alzheimer's disease and depression. Vol. 51, 1389-410. Accepted, .
  • Nemeroff CB, Levant B, Myers B, Bissette G (date unknown). Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies. Vol. 668, 146-56. Accepted, .